3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
12
Neoplasms
7
cyclopia sequence
6
Polycystic Ovary Syndrome
4
Fatigue
4
Obesity
3
Multiple Myeloma
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pain
2
Neoplasms, Plasma Cell
2
Hematologic Diseases
2
Head and Neck Neoplasms
2
Depression
2
Weight Loss
1
Warts
1
Vomiting
1
Vitamin D Deficiency
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sleepiness
1
Sezary Syndrome
1
Prostatic Intraepithelial Neoplasia
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Peripheral Nervous System Diseases
1
Periampullary Carcinoma Nos
1
Interventions
Doxorubicin
14
Radiotherapy
10
Ifosfamide
10
Trabectedin
7
pazopanib
4
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
Chemotherapy, Adjuvant
3
temsirolimus
2
romidepsin
2
ribociclib
2
pegfilgrastim
2
eribulin
2
cixutumumab
2
brigimadlin
2
belinostat
2
Vincristine
2
Sunitinib
2
Radiotherapy, Conformal
2
Gemcitabine
2
Epirubicin
2
Dexamethasone
2
Dactinomycin
2
Carboplatin
2
soblidotin
1
sitravatinib
1
siremadlin
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Liposarcoma
×
Sugars
×
Clear all
NCT02606461
2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3
Completed
342 enrolled
36 charts